Bone metabolism–related molecular targets

Bone metabolism–related molecular targets refers to a broad category of proteins and signaling pathways that regulate bone remodeling, a continuous process involving bone resorption by osteoclasts and bone formation by osteoblasts [1, 4]. Key molecular targets within this group include the Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), which is essential for osteoclast differentiation and survival, and Sclerostin (SOST), a glycoprotein that inhibits the Wnt/β-catenin signaling pathway to suppress bone formation [1, 3]. Other significant targets include the Parathyroid Hormone Receptor 1 (PTHR1), which mediates anabolic effects on bone, and Cathepsin K, a lysosomal protease involved in the degradation of the bone matrix [1, 3]. Dysregulation of these targets is central to the pathogenesis of metabolic bone diseases such as osteoporosis, Paget's disease, and bone metastases [1, 2]. Therapeutic agents targeting these molecules include denosumab (anti-RANKL), romosozumab (anti-sclerostin), and teriparatide (PTHR1 agonist) [1, 4]. Because this term describes a functional group of diverse receptors, ligands, and enzymes rather than a single molecular entity, it is considered a therapeutic category rather than a specific canonical target [3].

Other names

Bone remodeling targetsOsteometabolic targetsBone-directed therapeutic targets

Inhibition of osteoclast activity (antiresorptive) or stimulation of osteoblast activity (anabolic) through various pathways including RANKL/RANK, Wnt/β-catenin, and PTH signaling.